Medi Assist Q2 FY27 slides: margins expand as integration completes

Medi Assist reported Q2FY27 EBITDA up 23.9% to ₹49.2 crore and PAT up 167.5% to ₹21.6 crore, with EBITDA margin expanding 331 bps to 20.4% after completing the Paramount integration; revenue grew 3.9% year over year. Platform and SaaS revenue rose 112.7% in Q2, while the board approved a buyback of up to ₹49.3 crore at ₹425 per share and plans to return about 50% of cumulative adjusted free cash flow over rolling five-year periods. Management expects retention to recover from 90.5% to 93–94% within three to four quarters and core EBITDA margins to approach 22–23%; shares rose 2.88% to $303.70 following the presentation.

Analysis

The key underwriting question is whether margin recovery converts into durable per-share growth or merely marks the end of integration cleanup. With Paramount fully migrated, further margin gains toward the stated 22–23% range depend on execution and mix, not another discrete cost reset; modest Q2 revenue growth makes that target vulnerable if wage, technology, or service costs rise faster than sales. Over the next 1–3 months, retention and revenue conversion matter more than claims-volume or premium growth: management’s 93–94% retention target is a multi-quarter catalyst, while failure to improve from 90.5% would challenge both organic growth and the integration narrative.

The platform story has attractive operating leverage potential, but the near-term headline can overstate its financial weight. Fast growth is from a small base, and claims processed, platform premiums, and insurer go-lives are not equivalent to recurring, high-margin revenue. AI-led fraud savings primarily demonstrate customer value; investors should verify how much is contractually captured by Medi Assist through pricing or product attach rates. The 1.6% share-count benefit from the buyback is incremental, not a substitute for growth. Its stated ₹425 tender price versus the article’s reported ₹303.70 quote warrants verification of the quote currency, buyback mechanics, and eligibility before treating it as an arbitrage or price floor. Contrarian view: integration completion and cash returns may be priced as a clean inflection, while top-line acceleration and technology monetization remain unproven. Over 6–18 months, successful platform bundling could diversify growth; weak insurer conversion or retention would leave the business reliant on the mature TPA franchise.

Key Decisions for Investors

• Do not chase the margin-expansion headline alone. Track quarterly revenue growth, retention, and EBITDA margin together; a move toward 22–23% margins without improving revenue conversion is lower-quality growth.
• Treat MAtrix go-lives as a watch item, not a standalone buy signal. Before underwriting a platform rerating, verify incremental technology revenue, recurring contract economics, attach rates for higher-value products, and whether announced go-lives become paying production workloads.
• Potential long thesis: accumulate only on evidence that retention is recovering toward management’s 93–94% range and platform monetization is lifting organic revenue, while margins remain stable. Falsification: retention remains near 90.5% after the guided normalization window or margins retreat as integration benefits lapse.
• Do not trade the announced buyback as a price-floor or tender-arbitrage thesis until the ₹425 price, quoted market-price units, tender process, and shareholder eligibility are independently confirmed; the stated reduction in share count is modest.
• Near-term downside watch: slower insurer onboarding, continued retail TPA contraction without corresponding licensing revenue, or weak cash conversion despite reported profitability. These would expose the gap between operational activity metrics and shareholder-level earnings.